Disodium chromoglycate therapy in perennial rhinitis.
DSCG was tested on 38 patients with perennial rhinitis in the form of a nasal spray (2%)in a double-blind cross-over trial. Few of the investigated parameters in the whole material showed any significant preference of DSCG. A marked drug order effect was shown; in the group receiving placebo first, most of the clinical parameters assessed both by the clinician and the patient were better for DSCG. A therapeutical trial with DSCG is worth trying in perennial rhinitis.